Mainz Biomed appoints Michele Pedrocchi, to strategic advisory board

Mainz Biomed N.V., a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. Michele Pedrocchi to its Strategic Advisory Board.

“Having Michele join our Strategic Advisory Board is a fantastic addition given his prolific background in the in vitro diagnostics space,” commented Guido Baechler, Chief Executive Officer of Mainz Biomed. “Michele’s vast experience launching IVD products in multiple international markets is especially timely for our flagship product, ColoAlert which is in the early stage of its commercial lifecycle, and I’m looking forward to his counsel and direction as we expand ColoAlert’s commercial imprint across Europe and other international territories.”

Dr. Pedrocchi is a seasoned healthcare executive with over 25 years of international experience at Roche spanning in vitro diagnostics, digital health, and personalized medicine. During his tenure at Roche, Dr. Pedrocchi held senior leadership positions across corporate strategy, commercial and business development, including serving as Global Head of Strategy and Business Development for Diagnostics. Under his leadership, the division pioneered the entry into digital health and executed more than 20 acquisitions and 500 licensing deals. Prior leadership positions held at Roche included multiple international roles where Dr. Pedrocchi served as in-country and regional general manager and consistently built a track record of profitably growing businesses in emerging and mature markets. Moreover, he had an instrumental role in introducing patient selection through Companion Diagnostics (CDx) and establishing polymerase chain reaction (PCR) as a routine diagnostics methodology. Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.

“I am thrilled to join the Strategic Advisory Board of Mainz Biomed,” said Dr. Pedrocchi. “The Company is addressing a real issue in early cancer detection with a forward-looking approach: by extracting clinically relevant information from the combination of multiple markers and by making this accessible to a broader population via standardized laboratory kits, the company is going to have a major impact on patients around the world. I am truly looking forward to working with Guido and the team in making this happen.”

In his advisory role with Mainz Biomed, Dr. Pedrocchi will play an active role in supporting the Company’s business model of partnering with third-party laboratories, exploring distribution relationships and other types of commercial partnerships. In addition, Dr. Pedrocchi will support the management team as it evaluates strategic partnerships for Mainz’s pipeline of product candidates inclusive of licensing and M&A opportunities. Globe Newswire